Literature DB >> 2152822

Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus.

I Uhnoo1, M Riepenhoff-Talty, T Dharakul, P Chegas, J E Fisher, H B Greenberg, P L Ogra.   

Abstract

The pathogenic profiles of two heterologous animal rotaviruses, rhesus rotavirus strain MMU 18006 and bovine rotavirus strain WC3, were evaluated in mice with severe combined immunodeficiency (SCID mice) and normal BALB/c mice. Control animals were inoculated with homologous murine strain EDIM 5099 or a tissue culture-adapted murine rotavirus. Heterologous infection with rhesus rotavirus resulted in hepatitis in 84% of SCID and 21% of BALB/c mice, with mortality rates of 27 and 0%, respectively. Surviving SCID animals developed chronic liver disease, while symptoms in BALB/c mice resolved in 2 to 4 weeks after onset. Histopathologic examination revealed a diffuse hepatitis with focal areas of parenchymal necrosis. Rotavirus was detected in liver tissue from 100% of 29 SCID and 85% (11 of 13) BALB/c animals tested by cell culture infectivity, immunofluorescence, or electron microscopy. No extramucosal spread of virus or hepatitis was observed after infection with heterologous bovine strain WC3 or homologous murine rotaviruses. This finding of a novel rotavirus-induced disease manifestation suggests altered tissue tropism in a heterologous host for a group of viruses previously shown to replicate exclusively in the gut mucosa. The implications of our observations suggest that in human vaccine trials utilizing heterologous rotavirus strains, special attention should be paid to children with immunodeficiency disorders, and screening for hepatic function should be included in vaccine protocols.

Entities:  

Mesh:

Year:  1990        PMID: 2152822      PMCID: PMC249110     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Human rotavirus-like particles in a hepatic abscess.

Authors:  J E Grunow; S F Dunton; J L Waner
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

2.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.

Authors:  I de Zoysa; R G Feachem
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 3.  Human viral gastroenteritis.

Authors:  G Cukor; N R Blacklow
Journal:  Microbiol Rev       Date:  1984-06

4.  Identification of the rotaviral gene that codes for hemagglutination and protease-enhanced plaque formation.

Authors:  A R Kalica; J Flores; H B Greenberg
Journal:  Virology       Date:  1983-02       Impact factor: 3.616

5.  Molecular basis of reovirus neurovirulence: role of the M2 gene in avirulence.

Authors:  D B Hrdy; D H Rubin; B N Fields
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

6.  A murine model for oral infection with a primate rotavirus (simian SA11).

Authors:  P A Offit; H F Clark; M J Kornstein; S A Plotkin
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

7.  Virus-specific immunity in neonatal and adult mouse rotavirus infection.

Authors:  J F Sheridan; R S Eydelloth; S L Vonderfecht; L Aurelian
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

8.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

9.  Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children.

Authors:  T Vesikari; E Isolauri; A Delem; E D'Hondt; F E André; G Zissis
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

10.  Rapid diagnosis of rotavirus infection by direct detection of viral nucleic acid in silver-stained polyacrylamide gels.

Authors:  A J Herring; N F Inglis; C K Ojeh; D R Snodgrass; J D Menzies
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

View more
  29 in total

1.  Differential infection of polarized epithelial cell lines by sialic acid-dependent and sialic acid-independent rotavirus strains.

Authors:  M Ciarlet; S E Crawford; M K Estes
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18.

Authors:  Benyue Zhang; Benoit Chassaing; Zhenda Shi; Robin Uchiyama; Zhan Zhang; Timothy L Denning; Sue E Crawford; Andrea J Pruijssers; Jason A Iskarpatyoti; Mary K Estes; Terence S Dermody; Wenjun Ouyang; Ifor R Williams; Matam Vijay-Kumar; Andrew T Gewirtz
Journal:  Science       Date:  2014-11-14       Impact factor: 47.728

Review 3.  Pathogenesis of intestinal and systemic rotavirus infection.

Authors:  Robert F Ramig
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 4.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

5.  Symmetric infection of rotavirus on polarized human intestinal epithelial (Caco-2) cells.

Authors:  L Svensson; B B Finlay; D Bass; C H von Bonsdorff; H B Greenberg
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 6.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

7.  Rotavirus viremia and extraintestinal viral infection in the neonatal rat model.

Authors:  Sue E Crawford; Dinesh G Patel; Elly Cheng; Zuzana Berkova; Joseph M Hyser; Max Ciarlet; Milton J Finegold; Margaret E Conner; Mary K Estes
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 8.  The origin of major human infections and the crucial role of person-to-person spread.

Authors:  C A Mims
Journal:  Epidemiol Infect       Date:  1991-06       Impact factor: 2.451

9.  Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection.

Authors:  P A Offit; S L Cunningham; K I Dudzik
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Evaluating the safety of a rotavirus vaccine: the REST of the story.

Authors:  Joseph F Heyse; Barbara J Kuter; Michael J Dallas; Penny Heaton
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.